In this work, we showed theoretically that a rapid increase in tumor load in patients with advanced melanoma, soon after the onset of immunotherapy by pembrolizumab, can be due to relatively low toxicity of effector CD8+ T cells to cancer cells. The gene discussed is CD8A; the disease is cancer.